<span item_type="fundamental" item_id="d8241cce377f22edaf4b5e39ebc5a7ed" counter_id="ST/US/BTCY" env="prod"></span><span item_type="announcement" item_id="582790018294486657" env="prod"></span><p>Revenue: As of FY2026 Q2, the actual value is USD 3.886 M.</p><p>EPS: As of FY2026 Q2, the actual value is USD -0.029.</p><p>EBIT: As of FY2026 Q2, the actual value is USD 1.134 M.</p><p></p><h3>Financial Metrics by Segment</h3><h4>Revenue</h4><ul><li>Total revenue for the six months ended September 30, 2025, was $7,759,788, an increase from $6,468,589 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Total revenue for the three months ended September 30, 2025, was $3,885,795, an increase from $3,266,846 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Technology fee revenue for the six months ended September 30, 2025, was $6,882,846, an increase from $6,081,064 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Device sales for the six months ended September 30, 2025, were $876,942, an increase from $387,525 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li></ul><h4>Gross Profit</h4><ul><li>Gross profit for the six months ended September 30, 2025, was $6,298,298, an increase from $4,822,342 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Gross profit for the three months ended September 30, 2025, was $3,181,498, an increase from $2,459,174 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Gross margin for the six months ended September 30, 2025, was 81.2%, up from 74.6% for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Gross margin for the three months ended September 30, 2025, was 81.9%, up from 75.3% for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li></ul><h4>Operating Expenses</h4><ul><li>Selling, general, and administrative expenses for the six months ended September 30, 2025, were $4,443,573, a decrease from $5,214,983 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Selling, general, and administrative expenses for the three months ended September 30, 2025, were $2,304,881, an increase from $2,248,864 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Research and development expenses for the six months ended September 30, 2025, were $1,298,961, an increase from $1,031,877 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Research and development expenses for the three months ended September 30, 2025, were $602,798, an increase from $517,982 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Total operating expenses for the six months ended September 30, 2025, were $5,742,534, a decrease from $6,246,860 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Total operating expenses for the three months ended September 30, 2025, were $2,907,679, an increase from $2,766,846 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li></ul><h4>Profit (Loss) from Operations</h4><ul><li>Profit from operations for the six months ended September 30, 2025, was $555,764, compared to a loss of $1,424,518 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Profit from operations for the three months ended September 30, 2025, was $273,819, compared to a loss of $307,672 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li></ul><h4>Interest Expense</h4><ul><li>Interest expense for the six months ended September 30, 2025, was $1,710,673, an increase from $1,520,748 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Interest expense for the three months ended September 30, 2025, was $860,419, an increase from $752,075 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li></ul><h4>Accretion and Amortization Expenses</h4><ul><li>Accretion and amortization expenses for the six months ended September 30, 2025, were $355,713, a decrease from $1,484,616 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Accretion and amortization expenses for the three months ended September 30, 2025, were $202,141, a decrease from $339,888 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li></ul><h4>Change in Fair Value of Derivative Liabilities</h4><ul><li>Change in fair value of derivative liabilities for the six months ended September 30, 2025, was a loss of $33,971, compared to a loss of $500,619 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Change in fair value of derivative liabilities for the three months ended September 30, 2025, was a loss of $8,771, compared to a loss of $193,757 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li></ul><h4>Gain (Loss) upon Convertible Promissory Notes Conversion and Redemption</h4><ul><li>Gain upon convertible promissory notes conversion and redemption for the six months ended September 30, 2025, was $8,433, compared to a loss of $132,301 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Gain upon convertible promissory notes conversion and redemption for the three months ended September 30, 2025, was $0, compared to a loss of $4,690 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li></ul><h4>Other Income (Expense)</h4><ul><li>Other income for the six months ended September 30, 2025, was $173,270, compared to other expense of $193,486 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Other income for the three months ended September 30, 2025, was $106,599, compared to other income of $36,314 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li></ul><h4>Net Loss Before Income Taxes</h4><ul><li>Net loss before income taxes for the six months ended September 30, 2025, was $1,362,890, compared to $5,256,288 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Net loss before income taxes for the three months ended September 30, 2025, was $690,913, compared to $1,561,768 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li></ul><h4>Cash Flow</h4><ul><li>Net cash generated in operating activities for the six months ended September 30, 2025, was $42,241, compared to net cash used of $1,891,299 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>Free cash flow for the six months ended September 30, 2025, was $1,752,914, compared to -$370,551 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><ul><li>The Company plans to continue its revenue growth trajectory and improve liquidity through continued business development and additional equity and debt capitalization.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>The Company expects to devote significant resources to capital expenditures, research and development costs, and marketing and sales expenditures as it proceeds with the commercialization of Biocore and Biocare products.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>The Company believes its existing cash, along with anticipated near-term financings, will be sufficient to meet its needs for the next twelve months from the filing date of this report.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li></ul><h4>Non-Core Business</h4><ul><li>The Company may seek additional funds through arrangements with collaborators or other third parties to respond to business opportunities and challenges.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li><li>The Company is developing several other ancillary technologies that will require further FDA clearances, which it anticipates applying for within the next twelve months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1630113/000149315225023361/form10-q.htm"></span></li></ul>

Biotricity | 10-Q: FY2026 Q2 Revenue: USD 3.886 M